14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $8.74 $12.25 Thursday, 2nd May 2024 PHAT stock ended at $9.76. This is 5.40% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 5.24% from a day low at $9.36 to a day high of $9.85.
90 days $6.07 $12.25
52 weeks $6.07 $17.00

Historical Phathom Pharmaceuticals, Inc. prices

Date Open High Low Close Volume
Sep 27, 2023 $10.28 $10.52 $10.13 $10.31 189 722
Sep 26, 2023 $10.29 $10.90 $10.09 $10.26 252 522
Sep 25, 2023 $10.57 $10.75 $10.27 $10.48 591 590
Sep 22, 2023 $10.64 $10.79 $10.36 $10.63 237 693
Sep 21, 2023 $10.68 $10.99 $10.42 $10.62 550 459
Sep 20, 2023 $11.25 $11.60 $10.78 $10.86 637 318
Sep 19, 2023 $12.10 $12.11 $11.04 $11.08 1 430 971
Sep 18, 2023 $13.05 $13.29 $11.99 $12.11 445 847
Sep 15, 2023 $13.49 $13.94 $12.87 $13.10 1 792 276
Sep 14, 2023 $13.04 $13.63 $12.91 $13.47 416 357
Sep 13, 2023 $13.18 $13.75 $12.76 $12.97 366 947
Sep 12, 2023 $13.24 $13.83 $13.05 $13.14 225 780
Sep 11, 2023 $12.92 $13.75 $12.92 $13.31 336 399
Sep 08, 2023 $13.01 $13.12 $12.70 $12.74 250 802
Sep 07, 2023 $13.39 $13.86 $12.95 $13.01 312 178
Sep 06, 2023 $13.55 $13.71 $13.32 $13.49 309 090
Sep 05, 2023 $14.52 $14.74 $13.38 $13.61 372 962
Sep 01, 2023 $14.48 $14.70 $14.03 $14.52 318 960
Aug 31, 2023 $14.32 $14.81 $14.32 $14.39 210 125
Aug 30, 2023 $14.30 $14.63 $14.16 $14.35 137 413
Aug 29, 2023 $14.56 $14.84 $14.35 $14.36 144 949
Aug 28, 2023 $14.53 $14.70 $14.38 $14.61 242 829
Aug 25, 2023 $14.76 $15.06 $14.36 $14.43 156 070
Aug 24, 2023 $15.18 $15.33 $14.59 $14.73 158 104
Aug 23, 2023 $14.89 $15.46 $14.82 $15.15 319 647
Click to get the best stock tips daily for free!

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal re... PHAT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT